エディアル ファーマシューティカルズに関するコメント

A Major Breakthrough in Addiction Treatment: Adial Pharmaceuticals Secures a Key Patent.
Adial Pharmaceuticals, Inc., a trailblazer in developing therapies aimed at combating addiction and related disorders, has been granted a pivotal patent by the United States Patent and Trademark Office. This development, announced on April 22, 2024, marks a notable milestone in personalized medicine and offers new hope to millions battlin...

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder, or AUD, in heavy drinking patients and was recently investigated in the company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotype...